Trial · NCT00141102
Results by group44
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 44
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Subjects With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs) | Celecoxib | 20 | participants | ||
| Number of Subjects With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs) | Oral Diclofenac Plus Omeprazole | 81 | participants | ||
| Number of Subjects With CSULGIES or Symptomatic Ulcers (SUs) | Celecoxib | 25 | participants | ||
| Number of Subjects With CSULGIES or Symptomatic Ulcers (SUs) | Oral Diclofenac Plus Omeprazole | 92 | participants | ||
| Change From Baseline in Patient's Global Arthritis Assessment at Month 6/Early Termination (ET) | Celecoxib | 0.754 | Standard Error 0.020 | scores on a scale | |
| Change From Baseline in Patient's Global Arthritis Assessment at Month 6/Early Termination (ET) | Oral Diclofenac Plus Omeprazole | 0.773 | Standard Error 0.019 | scores on a scale | |
| Number of Subjects With SUs | Celecoxib | 5 | participants | ||
| Number of Subjects With SUs | Oral Diclofenac Plus Omeprazole | 11 | participants | ||
| Number of Subjects With CSULGIEs by History of GD Ulceration | Celecoxib | History of GD Ulceration (n=395, 400) | 7 | participants | |
| Number of Subjects With CSULGIEs by History of GD Ulceration | Oral Diclofenac Plus Omeprazole | History of GD Ulceration (n=395, 400) | 13 | participants | |
| Number of Subjects With CSULGIEs by History of GD Ulceration | Celecoxib | No History of GD Ulceration (n=1843, 1846) | 13 | participants | |
| Number of Subjects With CSULGIEs by History of GD Ulceration | Oral Diclofenac Plus Omeprazole | No History of GD Ulceration (n=1843, 1846) | 68 | participants | |
| Number of Subjects With Moderate to Severe Abdominal Symptoms | Celecoxib | 132 | participants | ||
| Number of Subjects With Moderate to Severe Abdominal Symptoms | Oral Diclofenac Plus Omeprazole | 162 | participants | ||
| Number of Subjects Withdrawn Due to GI Adverse Events (AEs) | Celecoxib | 114 | participants | ||
| Number of Subjects Withdrawn Due to GI Adverse Events (AEs) | Oral Diclofenac Plus Omeprazole | 167 | participants | ||
| Change From Baseline in Hemoglobin at Month 6/ET | Celecoxib | -0.017 | Standard Error 0.019 | grams (g)/deciliter (dL) | |
| Change From Baseline in Hemoglobin at Month 6/ET | Oral Diclofenac Plus Omeprazole | -0.423 | Standard Error 0.019 | grams (g)/deciliter (dL) | |
| Change From Baseline in Hematocrit at Month 6/ET | Celecoxib | -0.306 | Standard Error 0.059 | percent | |
| Change From Baseline in Hematocrit at Month 6/ET | Oral Diclofenac Plus Omeprazole | -1.425 | Standard Error 0.059 | percent |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00141102/results